anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Automatic diagnosis and brain hemorrhage segmentation in Computed Tomography (CT) may be helpful in assisting the neurosurgeon in developing treatment plans that improve the patient's chances of survival. Because medical segmentation of images is important and performing operations manually is challenging, many automated algorithms have been developed for this purpose, primarily focusing on certain image modalities. Whenever a blood vessel bursts, a dangerous medical condition known as intracranial hemorrhage (ICH) occurs. For best results, quick action is required. That being said, identifying subdural (SDH) and epidural haemorrhages (EDH) is a difficult task in this field and calls for a new, more precise detection method.
METHODS: This work uses a head CT scan to detect cerebral bleeding and distinguish between two types of dural hemorrhages using deep learning techniques. This paper proposes a rich segmentation approach to segment both SDH and EDH by enhancing segmentation efficiency with a better feature extraction procedure. This method incorporates Spatial attention- based CSR (convolution-SE-residual) Unet, for rich segmentation and precise feature extraction.
RESULTS: According to the study's findings, the CSR based Spatial network performs better than the other models, exhibiting impressive metrics for all assessed parameters with a mean dice coefficient of 0.970 and mean IoU of 0.718, while EDH and SDH dice scores are 0.983 and 0.969 respectively.
CONCLUSIONS: The CSR Spatial network experiment results show that it can perform well regarding dice coefficient. Furthermore, Spatial Unet based on CSR may effectively model the complicated in segmentations and rich feature extraction and improve the representation learning compared to alternative deep learning techniques, of illness and medical treatment, to enhance the meticulousness in predicting the fatality.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to piperidinyl-substituted methanoanthracenes of the formula (I)   where X and Y mean hydrogen atom; R 1  means pyridyl substituted with chiral (1-4C)-alkylsulfinyl-group and their pharmaceutically acceptable salts. Invention relates to also a pharmaceutical composition showing antagonistic activity with respect to Д1/Д2-dopamine and serotonine receptors and containing a compound of the formula (I) as an active component taken at effective dose. Invention relates to also a method of synthesis of compounds of the formula (I) by chiral oxidation of a compound of the formula (I) where X and Y - hydrogen atom; R 1  - pyridyl substituted with (C 1 -C 4 )-alkyl-S-group. For enantioselective oxidation a group (C 1 -C 4 )-alkyl-S is oxidized to chiral sulfoxide of the formula (C 1 -C 4 )-alkyl-SO. Obtained compound (I) is isolated or converted to a pharmaceutically acceptable salt which can be used as dopamine antagonists and as an antipsychotic agent for patients treatment. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 10 cl, 5 dwg, 4 ex
Broadly neutralizing antibodies (bnabs) and antigen binding fragments thereof that specifically bind to epitopes expressed by Hepatitis B Virus (HBV) are provided. The bNAb targets non-overlapping epitopes on HBV S antigen (HBsAg). Pharmaceutical compositions comprising bNAb or modified bNAb are provided. Also included are combinations of bnabs that are useful for preventing and treating HBV infection, as well as inhibiting the development of HBV escape mutations in infected individuals. Also included are expression vectors encoding the bnabs and antigenic fragments thereof, and methods for making the bnabs and antigenic fragments thereof. HBV peptides are provided for use as vaccines comprising at least two non-overlapping epitopes from HBsAg. Diagnostic reagents comprising bNAb or an antigenic fragment thereof are provided, as well as methods for detecting HBV and diagnosing HBV infection.
The cerebrovascular accident (CVA) is currently the leading cause of death in Brazil and it is estimated that there are about 62 million stroke survivors worldwide. Thus, the stroke sequels are a major public health problem not only in Brazil but in the world, with existing treatments often insufficient for complete recovery. Thus, the search for new treatments is necessary, as well as the need to optimize and individualize the existing treatments. Several approaches are being used in order to find predictors of the recovery of patients after the stroke, highlighting the most recent studies using magnetic resonance imaging (MRI) with tractography. However these studies have important limitations such as high cost, but mainly the low capacity of this technique to quantify brain plasticity known to play an important role in the recovery of stroke sequelae. Thus, techniques to measure brain plasticity theory offer the best potential to predict the resilience of post stroke injury, among which stands out transcranial magnetic stimulation (TMS).

TMS is a noninvasive brain stimulation techniques suitable for measuring the motor cortex excitability which in turn is used as an indirect measure of brain plasticity. Another interesting approach is the combination of TMS with the study of neuronal function through the electroencephalogram (EEG). The EEG under the stroke, has also been suggested as sequelae recovery predictor, however in this scenario the association of these findings with TMS has not yet been explored. Thus this study aims to identify predictors of different responses from rehabilitation therapy through the evaluation of clinical and neurophysiological data performed before and after treatment. For the neurophysiological study will be used the association of electroencephalogram (EEG) and transcranial magnetic stimulation (TMS). This last one will be performed in the baseline and after a single Transcranial direct current stimulation (tDCS) session, aiming to leverage the ability of those technics to analyze the cerebral plasticity.
Systems, methods, and apparatuses for automating a medical environment are described herein. Automation may be achieved using one or more sensing devices and at least one processing device. The sensing device may be configured to capture an image of the medical environment and provide the image to the processing device. The processing device may determine characteristics of the medical environment based on the images and automate one or more aspects of operations in the medical environment. These features may include, for example, the person and/or object present in the image and the respective location of the person and/or object in the medical environment. Operations that may be automated may include, for example, manipulating and/or positioning a medical device based on a position of a patient, determining and/or adjusting parameters of the medical device, managing a workflow, providing instructions and/or warnings to a patient or physician, and so forth.
Diabetes Mellitus (DM) is one of the most prevalent chronic pediatric diseases, affecting 2.80 cases per 1000 youth between the ages of 10 and 19. Since the crux of diabetes management is glucose regulation, any further challenges such as stress and/or poor sleep may make glucose regulation even more difficult. Mounting evidence supports the association between inadequate sleep and obesity as well as metabolic syndrome. Despite emerging findings supporting that total sleep time (TST) may contribute to the risk of obesity and/or metabolic complications, less research has been focused on Type 1 Diabetes Mellitus (T1DM) and on other sleep parameters.

Participants will have a Continuous Glucose Monitor (CGM) and actigraph placed which they will wear for 5 days. At the end of the 5 days, they will return the glucose meter, CGM, and actigraph to a clinic staff or research team member to download their data. They will provide us with a glucose log that contains the glucose levels obtained from a fingerstick capillary glucose meter. In this log, participants will also record their activities, meals, and insulin administered. They will also provide us with a sleep diary. In addition, participants will have the option for the child to undergo polysomnography (sleep study) for one night in their home or two nights in the sleep lab.
When Risperidone is co-administered with enzyme inducers (e.g., carbamazepine), the dose of Risperidone should be increased up to double the patient's usual dose. It may be necessary to decrease the Risperidone dose when enzyme inducers such as carbamazepine are discontinued [see Drug Interactions (7.1)]. Similar effect may be expected with coadministration of Risperidone with other enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital).

When fluoxetine or paroxetine is co-administered with Risperidone , the dose of Risperidone should be reduced. The Risperidone dose should not exceed 8 mg per day in adults when co-administered with these drugs. When initiating therapy, Risperidone should be titrated slowly. It may be necessary to increase the Risperidone dose when enzyme inhibitors such as fluoxetine or paroxetine are discontinued [see Drug Interactions (7.1)].
Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
The invention discloses a traditional Chinese medicine prescription for treating scrofula and red-hot needle therapy. The traditional Chinese medicine prescription includes centipede, Chinese violet, circium japonicum, rhizoma bletillae, fructus forsythiae, honeysuckle, radix bupleuri, square-stem, seaweed, radix astragali, Chinese angelica, platycodon grandiflorus, Indian buead, asparagus fern, buttercup roots and euphorbia helioscopia. A preparation method adopts a traditional Chinese medicine preparation method. The red-hot needle therapy adopts traditional Chinese medicine red-hot needle therapy. The traditional Chinese medicine prescription for treating scrofula and the red-hot needle therapy have effects of soothing liver-qi stagnation, nourishing yin, clearing away heat and toxic materials, softening hardness to dissipate stagnation, diminishing swellings, promoting tissue regeneration, tonifying qi-blood, addressing both symptoms and root causes and suppressing and killing scrofula. Particularly, a red-hot needle can directly kill the scrofula of a wound part, injection and medicines are integrated to treat scrofula of patients without recurrence, treatment rate of the patients with scrofula can achieve 98%, and cure rate of the patients achieves 96%.
The safety and effectiveness of olopatadine hydrochloride nasal spray for the relief of symptoms of seasonal allergic rhinitis have been established in pediatric patients aged 6 years and older.

The safety and effectiveness of olopatadine hydrochloride nasal spray in pediatric patients 6 to 11 years of age are supported by 3 vehicle-controlled 2-week studies in 870 patients [see Adverse Reactions (6.1)]. Doses studied included one and two sprays per nostril twice daily. One of these studies evaluated the safety of olopatadine hydrochloride nasal spray at doses of one and two sprays per nostril twice daily in 1,188 patients, of which 298 patients were exposed to olopatadine hydrochloride nasal spray 1 spray and 297 patients were exposed to vehicle 1 spray. In this study, the incidence of epistaxis with olopatadine hydrochloride nasal spray use was 5.7% [see Adverse Reactions (6.1), Clinical Studies (14)].

The safety and effectiveness of olopatadine hydrochloride nasal spray in pediatric patients aged 12 years and older are supported by 3 randomized, double blind, parallel group, multicenter, placebo-controlled clinical trials of 2 weeks duration in adult and adolescent patients [see Clinical Studies (14)]. In these studies, the incidence of epistaxis with olopatadine hydrochloride nasal spray use in 587 patients was 3.2% [see Adverse Reactions (6.1)].

The safety and effectiveness of olopatadine hydrochloride nasal spray have not been established in pediatric patients under 6 years of age.

The safety of olopatadine hydrochloride nasal spray at a dose of one spray per nostril twice daily was evaluated in one 2-week vehicle-controlled study in 132 pediatric patients 2 to 5 years of age with allergic rhinitis. In this trial, 66 patients were exposed to olopatadine hydrochloride nasal spray. The most common (greater than 1.0%) adverse reactions reported were diarrhea (9.1%), epistaxis (6.1%), rhinorrhea (4.5%), bitter taste (3.0%) and wheezing (3.0%). Diarrhea was reported more frequently (9.1%) in patients 2 to 5 years of age than 6 to 11 year old age group (< 1%).
PROBLEM TO BE SOLVED: To obtain a new isoprenylamine derivative, having a structure similar to that of isoprenylamines known as an antiviral agent and useful as a preventing and therapeutic agent for hepatopathy. SOLUTION: This new isoprenylamine derivative is represented by formula I [A is propenylene group, a 1-3C alkylene (which may be substituted with a 1-3C alkyl, etc.); Ar is phenyl (which may be substituted with a 1-4C alkyl, etc.); R is H or a 1-4C alkyl; (n) is an integer of 4-12], e.g. N-solanesyl-α- methylpropenylamine. The isoprenylamine derivative is obtained by converting an isoprenyl alcohol represented by the formula H-(CH2 -C(CH3 )=CH-CH2 )n -OH into an arylsulfonic acid ester and then reacting the resultant ester with an amine compound represented by formula II.
The invention discloses application of a Stat3 signal pathway inhibitor Static in treating an obesity phenotype caused by glucocorticoid. Glucocorticoids disrupt the mouse's intestinal proliferative apoptotic balance, leading to intestinal growth, and increase nutrient absorption, resulting in obesity. The drug Static is an inhibitor of Stat3 protein phosphorylation and dimerization, and directly inhibits activation of downstream signaling pathways of Stat 3. The expression of liver Fgf21 is regulated by Stat3, and the proliferation and apoptosis balance of intestinal tracts are influenced. In particular, the invention relates to Static inhibiting the expression of Stat3 gene or protein, inhibiting the growth of intestinal tract, reducing the absorption of nutrient substances and thus inhibiting the occurrence of obesity. Therefore, static can be used as a novel weight-losing drug of glucocorticoid obesity.
Participants will be recruited through the Children's Brain Tumor Foundation who will share the study announcement with their young adult members and social media. Eligible participants will complete a baseline battery survey via Qualtrics. The investigators will recruit 120 participants. The survey will take approximately 30 minutes to complete. Participants will be randomly assigned to an experimental group or control group. The experimental group will take an Internet-based behavioral activation intervention. The intervention has four modules and will be administered via Qualtrics. A link to each module will be sent to the participants via e-mail. Participants will have one week to complete each module. Once a participant completes a module, the next module link will be sent after 3 days. A reminder will be sent at 7 days and 10 days until the module is complete. Each module will take approximately 30 minutes to complete. The experimental group may continue to receive services as usual from the Children's Brain Tumor Foundation. The control group will continue to receive services as usual from the Children's Brain Tumor Foundation. The control group will have an opportunity to take the intervention once data collection is complete. Both groups will be asked to complete a battery of surveys at the end of the intervention and intermittently over a 3-month period.
Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
OBJECTIVE: Residual aortic dissection (AD) following DeBakey type I AD repair is associated with a high rate of adverse events that need additional intervention or surgery. This study aimed to identify clinical and early post-operative computed tomography angiography (CTA) imaging factors associated with adverse events in patients with type I AD after ascending aorta replacement.
METHODS: This single centre, retrospective cohort study included consecutive patients with type I AD who underwent ascending aorta replacement from January 2011 to December 2017 and post-operative CTA within three months. The primary outcome was AD related adverse events, defined as AD related death and re-operation due to aortic aneurysm or impending rupture. The location and size of the primary intimal tears, aortic diameter, and false lumen status were evaluated. Regression analyses were performed to identify factors associated with AD related adverse events. A decision tree model was used to classify patients as high or low risk.
RESULTS: Of 103 participants (55.43 ± 13.94 years; 49.5% male), 24 (23.3%) experienced AD related adverse events. In multivariable Cox regression analysis, connective tissue disease (hazard ratio [HR] 15.33; p < .001), maximum aortic diameter ≥ 40 mm (HR 4.90; p < .001), and multiple (three or more) intimal tears (HR 7.12; p < .001) were associated with AD related adverse events. The three year cumulative survival free from AD related events was lower in the high risk group with aortic diameter ≥ 40 mm and multiple intimal tears (41.7% vs. 90.9%; p < .001).
CONCLUSION: Early post-operative CTA findings indicating a maximum aortic diameter ≥ 40 mm and multiple intimal tears may predict a higher risk of adverse events. These findings suggest the need for careful monitoring and more vigilant management approaches in these cases.
PURPOSE: Accurate diagnosis and quantification of polyps and symptoms are pivotal for planning the therapeutic strategy of Chronic rhinosinusitis with nasal polyposis (CRSwNP). This pilot study aimed to develop an artificial intelligence (AI)-based image analysis system capable of segmenting nasal polyps from nasal endoscopy videos.
METHODS: Recorded nasal videoendoscopies from 52 patients diagnosed with CRSwNP between 2019 and 2022 were retrospectively analyzed. Images extracted were manually segmented on the web application Roboflow. A dataset of 342 images was generated and divided into training (80%), validation (10%), and testing (10%) sets. The Ultralytics YOLOv8.0.28 model was employed for automated segmentation.
RESULTS: The YOLOv8s-seg model consisted of 195 layers and required 42.4 GFLOPs for operation. When tested against the validation set, the algorithm achieved a precision of 0.91, recall of 0.839, and mean average precision at 50% IoU (mAP50) of 0.949. For the segmentation task, similar metrics were observed, including a mAP ranging from 0.675 to 0.679 for IoUs between 50% and 95%.
CONCLUSIONS: The study shows that a carefully trained AI algorithm can effectively identify and delineate nasal polyps in patients with CRSwNP. Despite certain limitations like the focus on CRSwNP-specific samples, the algorithm presents a promising complementary tool to existing diagnostic methods.
The invention describes the patterns of deamidation in gluten, and it is found that this is highly dependent on the spacing between the glutamine and proline residues. This knowledge can be used to predict novel T cell stimulatory gluten peptides. Several newly defined peptides and epitopes are provided.  Also, the finding can explain the formation of neo-epitopes in autoimmune diseases such as RA (rheumatoid arthritis), MS (multiple sclerosis), SLE  (systemic lupus erythomatosus), SS (Sjogren syndrome) and DB (diabetes).  Several neo-epitopes and the peptides that are substrate for deamidation are provided. Further, the inventions provides for methods for detecting these peptides and epitopes and methods for making food more suitable for celiac disease patients.
In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
In modern literature there is no conclusive evidence for the superiority of endoscopic over open inguinal hernia repair techniques, due to the lack of prospective, multicenter, randomized studies involving a sufficient number of patients. Both Lichtenstein and TAPP/TEP techniques are widely used and accepted methods of treatment. The clinical significance of this study is to show the differences in the incidence of perioperative complications, the evaluation of postoperative pain, full recovery time and improving the quality of life. The diagnosis of inguinal hernia will be based on a physical examination performed by an experienced surgeon based on the medical history of the patient and, if necessary, on ultrasound examination of the abdominal wall. Random assignment of patients to one of three treatment arms will take place the day before the surgery using computer-generated randomization list. The operating surgeon will be determined prior to randomization. Each patient before the study will receive complete information about the study which will be explained in detail regarding all planned procedures, the patient will obtain answers to any questions. After explaining any doubts the patient will sign the informed consent to participate in the study, in the presence of the investigator. Patients will be divided into three groups - TAPP, TEP and Lichtenstein method. Patients treated by TAPP and Lichtenstein will be further divided into subgroups - fixation glue or stitching - Lichtenstein method; fixation glue, tackers or implantation without fixation - TAPP method. Patients will receive preoperative antibiotic prophylaxis with a single dose of cephalosporin. Patients undergoing surgery will be hospitalized in the Department of Surgery until the first postop day. In justified cases, hospitalization will be extended.
The invention discloses a drug for treating bacillary dysentery. The drug as a traditional Chinese medicine composition comprises, by weight, 10-60 parts of Chinese angelica, 10-100 parts of white peony root, 10-60 parts of betel nut, 2-20 parts of bitter orange, 5-50 parts of talc, 1-60 parts of costus root, 1-20 parts of radish seed and 1-20 parts of licorice root. The drug can treat bacillary dysentery by treating intestines and stomach epidemic toxin, invigorating spleen and nourishing stomach, and rectifying qi and coursing liver and can improve effects by improving human immunity. The preparation method of an oral liquid containing the drug for treating bacillary dysentery has simple processes. The leached oral liquid can be fast absorbed by the human body and produce effects fast. Through a condensation technology, an oral liquid dosage is reduced and the oral liquid is convenient for carrying, preservation and taking.